Updated:
Shanghai MicroPort CardioFlow Medtech Co.
Shanghai MicroPort CardioFlow Medtech Co. — a medical device subsidiary developing transcatheter valve systems, publicly listed in Hong Kong since 2021.
Shanghai MicroPort CardioFlow Medtech Co.
Shanghai MicroPort CardioFlow Medtech Co. is a subsidiary of MicroPort Scientific Corporation, a Shanghai-based medical device group founded in 1998. The company focuses on structural heart disease, specifically transcatheter aortic valve replacement and mitral valve repair systems. CardioFlow was carved out as a standalone entity and listed on the Hong Kong Stock Exchange in February 2021. The company's strategy centers on developing and commercializing minimally invasive valve therapies for the Chinese and emerging Asian markets. Its product pipeline includes the VitaFlow transcatheter aortic valve system and the Tianxuan balloon-expandable aortic valve. CardioFlow also explores mitral and tricuspid valve replacement technologies. The firm operates primarily in China, with research and development in Shanghai. CardioFlow's scale is tied to MicroPort Scientific's broader operations, which reported over $800 million in revenue in 2022 across multiple subsidiaries. The firm has not disclosed standalone assets under management or investment professionals. A notable recent event: In November 2024, CardioFlow announced CE mark approval for its VitaFlow Liberty transcatheter aortic valve system, expanding its regulatory footprint into Europe. A structural differentiator is CardioFlow's position as a publicly traded subsidiary of a larger medical device conglomerate, a model common in Chinese medtech. This structure allows the parent to raise capital for specific therapeutic areas while retaining operational control. The division between CardioFlow's commercial operations and MicroPort's core R&D funding is a key governance feature.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Sector focus
Frequently asked questions
What is Shanghai MicroPort CardioFlow Medtech Co.'s primary business?
The firm develops and commercializes transcatheter valve replacement systems for structural heart disease. Its lead product, VitaFlow, is a self-expanding aortic valve system approved in China and now CE-marked for Europe. The company also explores mitral and tricuspid valve therapies (per public record, 2024).
Is CardioFlow a family office or an investment vehicle?
No — it is an operating medical device company, publicly listed on the Hong Kong Stock Exchange under the ticker 02160.HK. It does not function as a family office or asset manager. Its structure as a subsidiary of MicroPort Scientific Corporation means it reports standalone financials but operates within the parent group's governance.
How is CardioFlow related to MicroPort Scientific?
CardioFlow is a majority-owned subsidiary of MicroPort Scientific Corporation, which is listed on the Hong Kong Exchange as 00853.HK. MicroPort Scientific is a broader medical device group with subsidiaries in orthopedics, cardiovascular surgery, and diabetes care. CardioFlow focuses exclusively on structural heart disease (per public filings, 2021).
What are the key products in CardioFlow's pipeline?
The VitaFlow transcatheter aortic valve system is the flagship product, approved in China since 2019 and CE-marked in 2024. The Tianxuan balloon-expandable aortic valve is in a clinical trial. Early-stage work includes transcatheter mitral valve replacement and tricuspid valve therapies (per company announcements, 2024).
Where does CardioFlow operate geographically?
The firm's headquarters and primary R&D center are in Shanghai, China. Commercial sales are focused on the Chinese domestic market. The November 2024 CE mark for VitaFlow Liberty marks an initial expansion into European markets (per press release, November 2024).
Does CardioFlow have any disclosed institutional investors or partners?
As a publicly listed company, CardioFlow's shareholder base includes institutional investors, but specific names are not part of its core disclosures. The firm's IPO in 2021 raised approximately HKD 2.4 billion but did not name anchor investors in its official summaries.
What stage of development are CardioFlow's products in?
The VitaFlow aortic valve is commercialized in China. The VitaFlow Liberty received CE mark in November 2024, with European commercialization expected to begin in 2025. The Tianxuan aortic valve and mitral/tricuspid programs are in clinical or preclinical stages (per company filings, 2024).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: